28 Stocks Moving in Friday’s Pre-Market Session
Gainers
CAI International, Inc. (NYSE: CAI) rose 45.1% to $55.35 in pre-market trading after the company agreed to a $1.1 billion takeover by Mitsubishi HC Capital Inc.
50 Biggest Movers From Yesterday
Gainers
Verve Therapeutics, Inc. (NASDAQ: VERV) shares surged 68% to settle at $31.92 on Thursday after the company priced its IPO at $19 per share.
Tesla Partner CureVac Says Will Find ‘Sweet Spot’ For COVID-19 Vaccine Despite Disappointing Data
CureVac N.V.’s (NASDAQ: CVAC) Chief Financial Officer Pierre Kemula is optimistic its COVID-19 vaccine could still be offered to certain age groups or as a booster, the Financial Times reported o
Mid-Afternoon Market Update: Nasdaq Gains Over 100 Points; CureVac Shares Plummet
Toward the end of trading Thursday, the Dow traded down 0.67% to 33,806.27 while the NASDAQ rose 0.91% to 14,167.03. The S&P also fell, dropping 0.02% to 4,222.94.
Mid-Day Market Update: Gold Drops Over 4%; Midatech Pharma Shares Jump
Midway through trading Thursday, the Dow traded down 0.35% to 33,913.86 while the NASDAQ rose 0.73% to 14,142.60. The S&P also rose, gaining 0.07% to 4,226.52.
34 Stocks Moving In Thursday’s Mid-Day Session
Gainers
Cellect Biotechnology Ltd. (NASDAQ: APOP) shares jumped 68.5% to $5.51 after the company announced it filed a registration statement in connect with the proposed merger agreement with Quoin Pharmaceuticals.
25 Stocks Moving in Thursday’s Pre-Market Session
Gainers
Midatech Pharma plc (NASDAQ: MTP) rose 42.2% to $2.90 in pre-market trading after the company disclosed breakthrough data using Q-Sphera technology.
Tesla-Backed CureVac Plunges On Underwhelming COVID-19 Vaccine Efficacy Data
German vaccine developer, CureVac N.V. (NASDAQ: CVAC), may not be as fortunate as its domestic peer BioNTech SE (NASDAQ:
CureVac Issues PR Confirming Earlier News Co’s COVID-19 Vaccine Demonstrated An Interim Vaccine Efficacy Of 47% Against COVID-19 Disease Of Any Severity And Did Not Meet Prespecified Statistical Success Criteria
Pivotal study conducted in 10 countries in fast changing environment of at least 29 COVID-19 variant strains; original strain almost completely absent
At second interim analysis, statistical success criteria not met.